We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+14.95%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.78B
AUM Growth
-$802M
Cap. Flow
-$1.61B
Cap. Flow %
-18.35%
Top 10 Hldgs %
33.27%
Holding
157
New
20
Increased
27
Reduced
40
Closed
17

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$131M
2
MRK icon
Merck
MRK
+$97.5M
3
EW icon
Edwards Lifesciences
EW
+$97.4M
4
AGN.PRA
Allergan plc
AGN.PRA
+$76.2M
5
BOLD
Audentes Therapeutics, Inc
BOLD
+$72.9M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$213M
2
BMY icon
Bristol-Myers Squibb
BMY
+$184M
3
ABBV icon
AbbVie
ABBV
+$152M
4
BSX icon
Boston Scientific
BSX
+$141M
5
AGN
Allergan plc
AGN
+$138M

Sector Composition

Rank Sector Weight
1 Healthcare 92.67%
2 Financials 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XYLO
126
DELISTED
Xylo Technologies
XYLO
$756K 0.01%
375
– –
PTX
127
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$668K 0.01%
107,300
– –
XTNT icon
128
Xtant Medical Holdings
XTNT
$59.1M
$537K 0.01%
39,620
– –
ALPN
129
DELISTED
Alpine Immune Sciences Inc
ALPN
$480K 0.01%
+14,750
New +$359K
ALIM
130
DELISTED
Alimera Sciences
ALIM
$373K ﹤0.01%
16,667
– –
ARLZ
131
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$330K ﹤0.01%
68,143
– –
ALKS icon
132
Alkermes
ALKS
$8.07B
– –
-172,000
Closed -$7.43M
CAH icon
133
Cardinal Health
CAH
$54.6B
– –
-166,000
Closed -$12.9M
DVAX
134
DELISTED
Dynavax Technologies
DVAX
– –
-2,403,300
Closed -$35M
IBB icon
135
iShares Biotechnology ETF
IBB
$9.46B
– –
-159,900
Closed -$13.7M
INSM icon
136
CALL
Insmed
INSM
$22.5B
– –
-200,000
Closed -$1.97M
MCK icon
137
McKesson
MCK
$106B
– –
-43,400
Closed -$8.1M
MCRB icon
138
Seres Therapeutics
MCRB
$45.9M
– –
-4,300
Closed -$2.5M
MGNX icon
139
MacroGenics
MGNX
$234M
– –
-149,400
Closed -$4.03M
MOH icon
140
CALL
Molina Healthcare
MOH
$10.6B
– –
-350,000
Closed -$17.5M
SPY icon
141
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$775B
– –
-200,000
Closed -$41.9M
XBI icon
142
State Street SPDR S&P Biotech ETF
XBI
$9.97B
– –
-745,300
Closed -$40.3M
ONC
143
BeOne Medicines Ltd
ONC
$34B
– –
-12,925
Closed -$385K
ITCI
144
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-885,400
Closed -$35.8M
ADXS
145
DELISTED
Advaxis Inc
ADXS
– –
-29,693
Closed -$3.6M
WMGI
146
CALL
DELISTED
Wright Medical Group Inc
WMGI
– –
-400,000
Closed -$6.95M
RLYP
147
DELISTED
RELYPSA INC COM
RLYP
– –
-7,400,000
Closed -$137M
MDVN
148
DELISTED
MEDIVATION, INC.
MDVN
– –
-2,001,400
Closed -$121M
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2016 Portfolio in Review

As of Q3 2016, OrbiMed held 157 positions worth $8.78B, down 8.4% from $9.58B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed withdrew a net $1.61B in Q3 2016, closing 17 positions and reducing 40 holdings. Its most notable exit was RELYPSA INC COM, an estimated $137M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Allergan plc worth $72.5M.

  • OrbiMed's largest Q3 2016 buy was Allergan plc: 88,200 shares worth $72.5M.
  • OrbiMed added most to Shire pic in Q3 2016, an estimated $131M increase.
  • OrbiMed's biggest Q3 2016 reduction was HCA Healthcare, cutting an estimated $213M.
  • OrbiMed fully exited RELYPSA INC COM in Q3 2016, selling an estimated $137M.
  • OrbiMed's ten largest holdings make up 33% of its $8.78B portfolio in Q3 2016.
  • OrbiMed opened 20 new positions and closed 17 in Q3 2016.
  • OrbiMed's portfolio value fell 8.4% quarter-over-quarter to $8.78B.

Based on OrbiMed's 13F filing for Q3 2016, filed 14 Nov 2016.